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ORIGINAL INVESTIGATION
Effect of Moderate or Intensive Disease Management
Program on Outcome in Patients With Heart Failure
Coordinating Study Evaluating Outcomes of Advising and Counseling
in Heart Failure (COACH)
Tiny Jaarsma, PhD; Martje H. L. van der Wal, PhD; Ivonne Lesman-Leegte, MSc; Marie-Louise Luttik, PhD;
Jochem Hogenhuis, PhD; Nic J. Veeger, MSc; Robbert Sanderman, PhD; Arno W. Hoes, MD; Wiek H. van Gilst, PhD;
Dirk J. A. Lok, MD; Peter H. J. M. Dunselman, MD; Jan G. P. Tijssen, PhD; Hans L. Hillege, MD;
Dirk J. van Veldhuisen, MD; for the Coordinating Study Evaluating Outcomes of Advising and Counseling
in Heart Failure (COACH) Investigators
Background:: Heart failure (HF) disease manage-
ment programs are widely implemented, but data about
their effect on outcome have been inconsistent.
Methods: The Coordinating Study Evaluating Out-
comes of Advising and Counseling in Heart Failure
(COACH) was a multicenter, randomized, controlled trial
in which 1023 patients were enrolled after hospitaliza-
tion because of HF. Patients were assigned to 1 of 3 groups:
a control group (follow-up by a cardiologist) and 2 in-
tervention groups with additional basic or intensive sup-
port by a nurse specializing in management of patients
with HF. Patients were studied for 18 months. Primary
end points were time to death or rehospitalization be-
cause of HF and the number of days lost to death or hos-
pitalization.
Results: Mean patient age was 71 years; 38% were wom-
en; and 50% of patients had mild HF and 50% had mod-
erate to severe HF. During the study, 411 patients (40%)
were readmitted because of HF or died from any cause:
42% in the control group, and 41% and 38% in the basic
and intensive support groups, respectively (hazard ra-
tio, 0.96 and 0.93, respectively; P=.73 and P=.52, re-
spectively). The number of days lost to death or hospi-
talization was 39 960 in the control group, 33 731 days
for the basic intervention group (P =.81), and 34268 for
the intensive support group (P =.49). All-cause mortal-
ity occurred in 29% of patients in the control group, and
there was a trend toward lower mortality in the inter-
vention groups combined (hazard ratio, 0.85; 95% con-
fidence interval, 0.66-1.08; P=.18). There were slightly
more hospitalizations in the 2 intervention groups (ba-
sic intervention group, P =.89; and intensive support
group, P =.60).
Conclusions: Neither moderate nor intensive disease
management by a nurse specializing in management of
patients with HF reduced the combined end points of
death and hospitalization because of HF compared with
standard follow-up. There was a nonsignificant, poten-
tially relevant reduction in mortality, accompanied by a
slight increase in the number of short hospitalizations
in both intervention groups.
Clinical Trial Registry: http://trialregister.nl Identi-
fier: NCT 98675639
Arch Intern Med. 2008;168(3):316-324
H EART FAILURE (HF) IS ONEof the largest medicalproblems of our time, anddespite substantial ad-vances in its treatment,
morbidity and mortality remain high.1,2 In
recent years, various disease manage-
ment programs have been examined, and
in some, favorable effects on morbidity
(hospitalizations) and even mortality have
been reported.3-6 As a result, in many hos-
pitals, special disease management pro-
grams have been implemented such as an
HF clinic in which specialized nurses pro-
vide additional care.7
Although most studies have reported
favorable effects of a variety of these dis-
ease management programs, not all have
shown positive findings.8-10 Recent meta-
analyses also report effectiveness of HF dis-
ease management programs in reducing
mortality and hospital readmissions and
potential improvements in quality of life
and cost savings.11,12 Although some fac-
tors have been identified as important for
a successful program,13 it remains largely
unclear which components of the pro-
grams are primarily responsible for the ob-
served favorable effects and how inten-
sive such programs should be.
Author Affiliations are listed at
the end of this article.
Group Information: A list of
study investigators and
participating centers of the
Coordinating Study Evaluating
Outcomes of Advising and
Counseling in Heart Failure is
provided at the end of this
article.
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The present study was designed to examine the ef-
fects of a nurse-led disease management program in a suf-
ficiently large population with an assumed relatively high
event rate. The Coordinating Study Evaluating Out-
comes of Advising and Counseling in Heart Failure
(COACH) was designed to determine the effects of 2 lev-
els of intensity in disease management programs on the
combined end points of death and readmission to the hos-
pital. Patients who were eligible for COACH had been
hospitalized because of HF and were then randomized
to 1 of 3 treatment arms and studied for 18 months.
METHODS
COACH was a multicenter, randomized, open trial with blinded
endpoint evaluation, designed to compare basic support and in-
tensive support in patients with chronic HF, with a control group
receiving usual care as previously described in detail.14 Patients
were recruited during 28 months (October 23, 2002, to Febru-
ary 2, 2005), and all patients were followed up for a fixed period
of 18 months. The medical ethics committee approved the study
protocol, and all patients provided written informed consent.
PATIENT POPULATION
All patients had been admitted to the hospital with symptoms
of HF, New York Heart Association (NYHA) functional clas-
sification II to IV.14 The diagnosis was made on the basis of a
combination of typical signs and symptoms for which hospi-
talization was considered necessary, including the need for in-
travenously administered medication. All 17 sites were expe-
rienced HF centers that had participated in multicenter HF trials.
Patients were 18 years or older and had evidence of structural
underlying heart disease as shown at cardiovascular imaging.
Both patients with impaired left ventricular ejection fraction
(LVEF) and those with preserved LVEF could participate. Be-
fore discharge from the hospital (ie, before inclusion in the
study), patient status had to be stable with standard medica-
tion for HF. The decision to enroll a patient in the study was
made at the participating center. Major exclusion criteria were
concurrent inclusion in another study or HF clinic, inability
to complete the questionnaires, invasive procedure or cardiac
surgery intervention performed within the last 6 months or such
procedure or intervention planned to be performed within the
next 3 months, ongoing evaluation for heart transplantation,
and inability or unwillingness to give informed consent.
RANDOMIZATION
During hospitalization, patients were randomized to 1 of 3
groups, as follows: basic support, intensive support, or con-
trol.14 The computer-generated randomization scheme used ran-
dom permuted blocks of 6 patients stratified per center to en-
sure balanced assignment of patients to each of the 3 groups
in each of the 17 participating centers.
INTERVENTION STRATEGIES
The study included 2 types of intervention and a control treat-
ment.14 Figure 1 shows the intensity of contacts with the car-
diologist and nurse specializing in management of patients with
HF (HF nurse) during follow-up. All patients received usual rou-
tine management by their cardiologist. This included an outpa-
tient visit less than 2 months after hospital discharge and then
every 6 months. Because 17 hospitals were involved, with po-
tential differences in follow-up intensity, a standardized fol-
low-up schedule was developed. Patients in the 2 support groups
were visited by an HF nurse during admission, for education and
support, and were scheduled for additional visits at the outpa-
tient clinic.
Patients in the basic support group were scheduled for ad-
ditional visits to the HF nurse at the outpatient clinic. Patients
were educated using a protocol, and behavioral strategies were
used to improve adherence. In addition, patients were in-
structed to contact the nurse if there was any change in their
condition. Patients in the intensive support group received a
similar intervention as used in the basic support group except
they had monthly contact with the nurse. In the first month
after hospital discharge, weekly telephone contacts were made
and the patient was visited at home by the HF nurse. Further-
more, telephone calls, 2 home visits, and multidisciplinary ad-
vice given by a physiotherapist, dietician, and social worker were
part of the intensive support intervention. In addition to pro-
viding information to patients, HF nurses were trained to in-
crease patient self-efficacy. Materials used in the intervention
included a patient diary, brochures on HF and its manage-
ment, and samples of sodium-restricted food seasonings. Pa-
tients in both intervention groups were instructed to seek help
if symptoms increased or if they gained weight.
Patients in the control group did not receive any treatment
other than standard management by their cardiologist. All nurses
were trained to increase the self-efficacy of the patients, and
the quality of the 2 study interventions was maintained by
monthly site visits of the research team to confirm adherence
to the protocol.
FOLLOW-UP AND DATA COLLECTION
All patients were examined at hospital discharge and for 18
months thereafter.14 Data on mortality and number of readmis-
sions to the hospital were collected from medical records and
patient interviews. Cause of death, reason for readmission, and
date of the event was adjudicated by a central end-point com-
mittee whose members were blinded to group assignment.
END POINTS
The study had 2 primary end points.14 The first primary end
point was a composite of HF hospitalization or death from any
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Figure 1. Protocol for contacts with health care providers (cardiologists and
specially trained nurses) in the 3 groups.
(REPRINTED) ARCH INTERN MED/ VOL 168 (NO. 3), FEB 11, 2008 WWW.ARCHINTERNMED.COM
317
©2008 American Medical Association. All rights reserved.
 at University of Groningen, on April 29, 2008 www.archinternmed.comDownloaded from 
planned overnight stay in a hospital because of progression of
HF or as a direct result of HF. Patients had to have typical signs
and symptoms, and hospitalizations were classified as HF-
related if admission was primarily for treatment of HF or when
HF became a major component of the patient’s hospital admis-
sion according to a predefinedManual of Operations for COACH
using standard criteria.15 Evidence of worsening HF was also
classified using standard clinical criteria.15 The second pri-
mary end point was the number of “unfavorable days,” de-
fined as the number of days lost because of death or hospital-
ization during the 18 months of follow-up. Major secondary end
points were the 2 individual components of the composite end
point, that is, death from any cause and hospitalization because
of HF, and the number of all-cause hospitalizations per patient.
All reported deaths and hospital admissions were referred to and
adjudicated by an independent clinical event committee (see
“COACH Investigators” section at the end of the article), who
were blinded to the allocation of the interventions.
SAMPLE SIZE
We assumed a 40% event rate for the primary end points (death
or readmission to the hospital because of HF) in the control
group within the first year.14 A 25% decrease in events in the
basic support group was considered both realistic and clini-
cally relevant. With a power of 90% and an  level of .05, 349
patients were required in each of the 3 groups.
STATISTICAL ANALYSIS
All analyses were conducted according to the intent-to-treat prin-
ciple.14 There were 2 primary end point comparisons: time to
first major event (death or hospitalization because of HF) and
the number of days lost because of death or hospitalization.
Kaplan-Meier curves were constructed for the different time
to event evaluations, and groups were compared using the log-
rank test. To estimate the size of the effect, hazard ratios (HRs)
with 95% confidence intervals (CIs) were calculated with the
use of unadjusted Cox regression models. The number of days
lost because of death or hospitalization during the 18 months
of follow-up and the number of hospitalizations per patient were
calculated and tested between groups using the Mann-
Whitney test. All analyses were prespecified; reported P val-
ues are 2-sided and have not been adjusted for multiple test-
ing. Dependency of multiple hospitalizations in 1 patient has
not been considered in testing differences in incidences of hos-
pitalization because of HF and duration of hospitalizations.
P .05 was considered statistically significant. Statistical analy-
ses were performed using commercially available software (SPSS
version 12.0; SPSS Inc, Chicago, Illinois, and SAS version 9.1;
SAS Institute Inc, Cary, North Carolina).
RESULTS
During the study, 2957 patients were hospitalized be-
cause of symptomatic HF and structural underlying heart
disease (Figure 2). A total of 1908 patients were ex-
cluded. Of these, 1117 patients did not meet the inclu-
sion criteria because they were already enrolled in the
HF clinic or another trial (n=336); were unable to fol-
low the study protocol owing to dementia, other psychi-
atric illness, or deafness (n=328); had a planned or re-
cent invasive procedure or surgery (n=292); had a
terminal illness or were receiving palliative treatment
(n=125); or died before randomization (n=36). An ad-
ditional 282 patients refused to participate, and 509 were
excluded because of other, usually logistic, reasons. Pa-
tients who participated were, on average, 4 years younger
and more often male (63% vs 51%) compared with non-
participants. A total of 1049 patients were randomized
during hospitalization because of HF, of whom 1023 were
discharged alive and were followed up for 18 months;
this latter group forms the present study population.
BASELINE CHARACTERISTICS
The baseline characteristics of the 3 groups were com-
parable. Mean age was 71 years (age range, 23-93 years),
62% were men, and 61% were married (Table 1).
Control Group
348 Assigned to receive intervention
338 Receive intervention as assigned
9 Died before hospital discharge
1 Crossed over to basic support
2957 Assessed for Eligibility 
1908 Excluded 
1117 Not meeting inclusion criteria 
282 Refused to participate 
509 Other reasons, eg, short hospital 
admission or no transportation 
1049 Randomized 
0 Lost to follow-up 
339 Included in the analysis 
Basic Support Group
348 Assigned to receive intervention
338 Receive intervention as assigned
8 Died before hospital discharge
1 Crossed over to intensive support
0 Lost to follow-up 
340 Included in the analysis 
Intensive Support Group
353 Assigned to receive intervention
344 Receive intervention as
       assigned
9 Died before hospital discharge
0 Lost to follow-up 
344 Included in the analysis 
Figure 2. Flow of participants through the trial.
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Whereas at admission to the hospital, virtually all pa-
tients had NYHA functional class III or IV disease, at dis-
charge, 50% were classified as having NYHA class II dis-
ease and 50% as having NYHA III or IV disease. Both
patients with decreased LVEF and preserved LVEF were
included, and the mean LVEF was 34%.
INTERVENTION
There was a substantial difference in contacts with the
study cardiologists and the specially trained nurses in all
3 groups compared with the planned protocol (Figure 1).
Control patients were supposed to visit the cardiologist
only 4 times and to have no contact with an HF nurse.
According to this schedule, 858 visits to the cardiologist
should have taken place, but an actual total of 1144 vis-
its to the cardiologist were made (286 additional visits,
or 33% more). In the basic support group, 2347 visits
and telephone calls were planned, but 3302 visits or tele-
phone calls (40% more) were actually made. In the in-
tensive support group, 5868 visits and telephone calls were
planned and 6469 (10% more) were made. The esti-
mated time investment of nurses in the basic support
group was 20 hours per patient, and in the intensive in-
tervention group was 40 hours per patient. Two pa-
tients crossed over to another group, 1 patient from the













Age, mean (SD), y 71 (11) 72 (11) 71 (11) 70 (12)
Female sex 384 (38) 136 (40) 115 (34) 133 (39)
LVEF, mean (SD) 34 (14) 34 (14) 34 (14) 33 (15)
NYHA functional classa
II 513 (50) 177 (54) 171 (51) 165 (48)
III 461 (46) 139 (42) 159 (47) 163 (48)
IV 34 (4) 13 (4) 8 (3) 13 (4)
Blood pressure, mean (SD), mm Hg
Systolic 118 (21) 119 (22) 118 (20) 117 (21)
Diastolic 68 (12) 68 (12) 69 (13) 68 (12)
Heart rate at hospital discharge, mean (SD), beats/min 75 (14) 75 (14) 75 (13) 74 (14)
Previous hospital admission because of HF, No. (%) of patients 334 (32) 120 (35) 108 (32) 106 (31)
Comorbidities
Hypertension 439 (43) 157 (46) 152 (45) 130 (38)
Atrial fibrillation 372 (36) 121 (36) 122 (36) 129 (37)
Diabetes 289 (28) 103 (30) 98 (29) 88 (26)
Stroke 105 (10) 37 (11) 35 (10) 33 (9)
COPD 268 (27) 84 (25) 87 (26) 97 (28)
History of MI 436 (43) 149 (44) 144 (42) 143 (42)
Index hospital stay, median (range), d 10 (7-16) 11 (7-16) 10 (7-16) 10 (7-17)
Living alone 396 (39) 139 (42) 136 (41) 121 (35)
Body mass index, mean (SD)b 27 (5) 27 (5) 27 (5) 27 (5)
Duration of disease, median (range), y 1 (0-34) 1 (0-34) 1 (0-29) 1 (0-22)
eGFR, mean (SD), mL/min/1.73 m2 55 (21) 52 (20) 57 (19) 57 (23)
Medication
ACEI or ARB 847 (83) 277 (82) 290 (85) 280 (81)
-Blockers 677 (66) 221 (65) 239 (70) 217 (63)
Diureticsc 980 (95) 325 (96) 330 (97) 325 (95)
Digoxin 309 (30) 100 (30) 108 (32) 101 (29)
Calcium antagonists 162 (16) 60 (18) 57 (17) 45 (13)
Nitrates 324 (32) 109 (32) 101 (30) 114 (33)
Statins 388 (38) 126 (37) 141 (42) 121 (35)
Laboratory values
BNP, median (IR), pg/dL 493 (730) 530 (986) 478 (657) 478 (634)
NT-proBNP, median (IR), pg/dL 2528 (4291) 2677 (5251) 2404 (3903) 2505 (4274)
Serum sodium, mean (SD), mEq/L 139 (4) 139 (4) 139 (4) 139 (4)
Hemoglobin, mean (SD), g/dL 13.2 (1.9) 12.9 (1.9) 13.2 (2.1) 13.2 (1.9)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; IR, interquartile range; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; NYHA, New York Heart Association.
SI conversion factors: To convert sodium to millimoles per liter, multiply by 1.0; hemoglobin to grams per liter, multiply by 10.0.
aClass II indicates mild (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea); III,
moderate (marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea); and IV, severe (unable
to carry out any physical activity without discomfort; symptoms of cardiac insufficiency at rest; if any physical activity is undertaken, discomfort is increased).
bCalculated as weight in kilograms divided by height in meters squared.
c Includes loop diuretics, thiazides, and aldosterone antagonists.
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Figure 3. End points. A, Kaplan-Meier curve for time to death or first hospitalization because of heart failure (primary end point). B, Kaplan-Meier curve for
all-cause mortality (major secondary end point).
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basic support group to the intensive support group and
1 patient from the control group to the basic support




During the 18 months of the study, 411 of 1023 patients
(40%) reached the primary end point (death or hospital-
ization because of HF): 141 patients (42%) in the control
group, 138 patients (41%) in the basic support group, and
132 patients (38%) in the intensive support group. Analy-
sis of the time to first event showed HRs of 0.96 (95% CI,
0.76-1.21; P=.73) and 0.93 (95% CI, 0.73-1.17; P=.53)
for the composite end point of death and hospitalization
because of HF in the basic and intensive support groups,
respectively, vs the control group (Figure 3A).
The total number of days lost because of death or all-
cause hospitalization during the 18-month study (the other
primary end point) was 39 960 days in the control group
compared with 33 731 days in the basic support group and
34 268 in the intensive support group (Figure4). Per pa-
tient, the median number of days lost was 12 in the con-
trol group (25th and 75th percentiles, 0.0 and 173.0 days),
9 in the basic support group (25th and 75th percentiles,
0.0 and 88.0 days; P=.81 vs control group), and 71⁄2 in the
intensive support group (25th and 75th percentiles, 0.0 and
86.5 days; P=.49 vs control group).
SECONDARY END POINTS
Mortality
The all-cause mortality rate was 29% in the control group,
27% in the basic support group, and 24% in the inten-
sive support group (Figure 3B). The 12% and 19% re-
ductions in mortality rate during the 18 months were not
statistically significant, with HR of 0.88 (95% CI, 0.66-
1.18; P=.39) and HR of 0.81 (95% CI, 0.60-1.08; P=.15).
For the 2 intervention groups combined, the HR was 0.85
(95% CI, 0.66-1.08; P=.18).
Hospitalizations
Of all patients, 55% were hospitalized at least once for
any cause during the 18 months, for a total of 1161 hos-
pitalizations (Table 2). A total of 64% (746) of these
hospitalizations were considered related to cardiovascu-
lar disorders, but only 32% (375) were related to HF.
There were slightly more hospitalizations because of HF
in the intensive support group compared with the con-
trol group (134 vs 120). Considering a total cumulative
follow-up of 429.02 years for the intensive support group
and 409.27 years for the control group, incidence rates
of 0.31 and 0.29 per follow-up year were calculated for
the intensive support and control groups, respectively,
with an incidence rate ratio of 1.07 (95% CI, 0.83-1.37;
P=.62). However, the median duration of admissions to
the hospital because of HF in both support groups (8.0
days in the basic support group and 9.5 days in the in-
tensive support group) was shorter compared with the
control group (12.0 days; basic support group vs con-
trol group, P=.01, and intensive support vs control group,
P=.29 (Table 2). There was no difference between groups
with respect to the proportion of patients who had mul-
tiple readmissions to the hospital because of HF.
COMMENT
The primary findings of this randomized controlled study,
which, to our knowledge, is one of the largest to date in
the field of HF disease management, do not support the
concept that adding either a basic or an intensive nurse-
led management program to standard care of a cardiolo-
gist reduces the combined end point of death or rehos-
pitalization because of HF. We did, however, observe a
nonsignificant but potentially clinically relevant 15% de-
crease in all-cause mortality, which was accompanied by
a slight increase in (shorter) hospitalizations in both in-
tervention groups.
Disease management programs are implemented on a
large scale in many countries, and recent guidelines ad-
vocate the use of an organized system of specialist HF care
to improve symptoms and reduce hospitalizations (class
IA) and to increase survival (class IB).1,2 In the present large
study in 17 centers, we did not find an effect on the com-
posite end point of death and hospitalization because of
HF. Given the existing data, this finding is unexpected and
will affect the role of disease management programs for
HF and HF guidelines. It is, therefore, important to iden-
tify factors that may have led to this outcome.
The 2 most obvious explanations for the absence of a
difference in the event rate between the control and in-
tervention groups are that either patients in the control
group were managed well enough already, thus making
it difficult to further improve outcomes, or the quality of
the intervention did not improve treatment. We believe
that the first explanation, in particular, may have an im-
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Figure 4. Number of days lost because of death or hospitalization during 18
months of follow-up (composite primary end point).
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expected event rate in the control group, which is often
noted in clinical trials. In earlier studies, patients in the
control group did not receive any structured specialized
follow-up, which might be associated with higher rates of
mortality and hospitalization.11,12 In our study, however,
control patients were seen by a cardiologist, which con-
stitutes usual care in the health care system in the Neth-
erlands. Moreover, the 339 patients in the control group
had an additional 286 visits to their cardiologist, often be-
cause of an increase in symptoms. It is likely that these
visits “upgraded” the control group and led to better ad-
herence to medication, which is known to be associated
with a better outcome.16 Although patients in the 2 inter-
vention groups also had more visits than planned, it is con-
ceivable that this surplus of visits had the largest effect in
the control group. Although specific measures were taken
during the study to avert extra contacts14 and we discour-
aged local investigators to have these unplanned visits, we
often could not prevent them because in patients whose
condition deteriorated, the cardiologist intensified con-
tacts. The alternative explanation for the absence of a con-
trast between the groups might be that the additional sup-
port in the 2 intervention groups was not successful enough
in educating and counseling patients. Although this can-
not be proved, we believe that this latter explanation is not
likely inasmuch as substantial time and effort was spent
by specially educated and experienced workers to im-
prove knowledge about HF and its treatment, which is well
known to be important in this population.17
A comparable increase in the number of hospital ad-
missions in combination with a decrease in mortality has
been reported previously with intervention programs in
HF.9,18 Cleland et al18 reported the highest percentage of
days spent in the hospital in patients who were moni-
tored most intensively (by nurse visits and telephone
calls). Health care providers might be forced to realize
that readmissions to the hospital because of HF are part
of the need in these severely ill patients and should not
always be considered negative. The present study showed
that a one-size-fits-all model of disease management does
not reduce readmissions in every hospital, and institu-
tions may differ substantially in their organization and
expertise in the treatment of HF.
While the number of hospitalizations in the present
study was not favorably affected, there was a 15% (non-
significant) reduction in mortality that was consistent
throughout the follow-up and confirms findings of pre-
vious meta-analyses.11,12 This reduction is comparable to
proved pharmacologic interventions in this population,
and although the study was not powered to examine mor-
tality, it is substantial. We found that the separate com-
ponents of the composite end point moved in opposite
directions, reflected by a higher readmission rate and a
lower mortality rate. Patients in both intervention groups
may have had low-threshold access to the care provid-
ers, resulting in relatively easy admission to the hospi-
tal. For this reason, hospitalizations being part of the pri-
mary end point may not have been ideal and we might
have powered the study for mortality alone. Also, while
hospitalizations may possibly be affected by subjective
factors, such an effect is unlikely when assessing mor-
tality, and the present finding may, thus, be genuine.
Most, if not all, previous studies that evaluated the effect
of programs in a similar (clinical) setting as COACH were
relatively small and conducted primarily in 1 or only a
few sites.11,12 While COACH is the largest study in this














Death or hospitalization because of HF 411 (40) 141 (42) 138 (41) 132 (38)
No. of days lost in 18 months 107 959 39 960 33 731 34 268
No. of days lost per patient, median (25th
and 75th percentiles)
10.0 (0.0-109.0) 12.0 (0.0-173.0) 9.0 (0.0-88.0) 7.5 (0.0-109.0)
Other events
Hospitalization
All causes 567 (55) 181 (53) 192 (57) 194 (56)
Cardiovascular disease 433 (42) 143 (42) 143 (42) 147 (43)
HF 260 (25) 84 (25) 84 (25) 92 (27)
No. of hospitalizations
All causes 1161 376 377 408
Cardiovascular disease 746 255 236 255
HF 375 120 121 134
Death
All causes 272 (27) 99 (29) 90 (27) 83 (24)
Cardiovascular disease 219 (21) 72 (21) 76 (22) 71 (21)
Noncardiovascular disease 38 (4) 19 (6) 10 (5) 9 (3)
Unknown cause 15 (2) 8 (2) 4 (1) 3 (1)
Duration of hospitalization because of HF,
median (25th and 75th percentiles), d
9.0 (5.0-17.0) 12.0 (5.0-19.5) 8.0 (4.0-14.0) 9.5 (5.0-17.0)
Abbreviation: HF, heart failure.
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clinical setting, there are 2 even larger studies, but both
had a completely different design and examined the effect
of (additional) telephone intervention.19,20 Galbreath et
al19 studied 1069 patients with HF in a single center and
showed that initial weekly and later monthly telephone
intervention led to a borderline statistically significant
reduction in all-cause mortality during an 18-month study.
In another study from Argentina,20 1518 outpatients with
HF were enrolled, and the investigators found a statis-
tically significant 29% reduction in hospital admissions
because of HF but no effect on mortality. Two other stud-
ies, which were more similar to COACH and reported
the most pronounced favorable effects, were conducted
in only 2 or 3 dedicated and experienced hospitals.4,21 Fa-
vorable effects observed in other studies may also be at-
tributed to the other components in the programs, but
also to direct involvement of the researchers conduct-
ing the study in delivering care. It also cannot be ruled
out that studies with positive findings were published
more often than studies with negative findings, leading
to publication bias.
COMMENT
The findings of the present large study, at first glance, seem
to be in contrast to those of earlier similar studies, but we
believe that they should not lead to abandoning the con-
cept of disease management programs for HF; rather, they
must lead to more precise definitions of how such pro-
grams should be implemented. These data will contribute
to the discussion of optimal design and execution of dis-
ease management in patients with HF and indicate that one
model does not fit all patients or all health care systems.
Hospital admissions contribute substantially (60%-
70%) to costs of treating patients with HF, and in our study,
the threshold may have been too low to admit patients to
the hospital. Organizing these short hospitalizations ef-
fectively is one of the major challenges in the future. The
observed effect on mortality, albeit not statistically sig-
nificant, is promising because mortality is a pivotal clini-
cal end point in patients with HF. It suggests that this non-
pharmacologic intervention may have been successful in
preventing progression of the disease.
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